RxSight INVESTOR ALERT: Edelson Lechtzin LLP Urges RxSight, Inc. (NASDAQ: RXST) Shareholders With Substantial Losses to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against RxSight, Inc. for misleading statements regarding its business and financial performance during the specified Class Period [1][4]. Company Background - RxSight, Inc. is a commercial-stage medical technology company that specializes in the research, development, manufacturing, and marketing of light-adjustable intraocular lenses (LAL) used in cataract surgery [3]. Securities Fraud Claims - The class action complaint alleges that RxSight made materially false and misleading statements, failing to disclose declines in product sales and utilization, and overstating demand for its intraocular lens products [4]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. Financial Performance - On July 9, 2025, RxSight reported significant declines in sales of its Light Delivery Device (LDD), usage of its light-adjustable intraocular lenses (LALs), and total revenue, leading to a reduction in its Full Year 2025 guidance by approximately $42.5 million [5]. - Following this disclosure, RxSight's stock price fell by $4.84 per share, or 37.8%, closing at $7.95 per share on July 9, 2025 [5].